{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:51:39Z","timestamp":1792785099155,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Stanford Cancer Institute, an NCI- designated Comprehensive Cancer Centre and the Stanford Department of Surgery Equipment Grant","id":[{"id":"https:\/\/ror.org\/014qe3j22","id-type":"ROR","asserted-by":"crossref"}]},{"name":"John and Marva Warnock Endowed Scholar Fund"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BJC Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Current spatial proteomic approaches quantify immune checkpoint expression but do not directly measure functional receptor-ligand (PD-1\/PD-L1) interactions within the tumour-immune microenvironment (TiME). Therapeutic antibodies disrupt receptor-ligand interactions and do not target protein abundance; therefore, methods capable of resolving functional checkpoint interactions may provide biologically distinct insight beyond expression-based assays.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We developed FuncO:TiME by integrating functional oncology mapping (FuncOmap), histopathology and multiplex spatial immune profiling to map PD-1\/PD-L1 interaction states within clinically annotated melanoma tissues collected before and after neoadjuvant immune checkpoint blockade (ICB).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>FuncOmap quantified millions of per-pixel PD-1\/PD-L1 interactions and revealed marked spatial heterogeneity in checkpoint interactions that were not reflected by PD-1 or PD-L1 expression alone. Post-treatment tissues exhibited increased PD-1\/PD-L1 interaction states despite no corresponding increase in expression, highlighting the divergence between functional checkpoint interactions and expression-based measurements. Integrating with spatial immune profiling further demonstrated the feasibility of contextualising regional differences in interaction states within distinct immune populations and patterns of PD-1\/PD-L1 expression in melanoma TiMEs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We establish the feasibility of FuncO:TiME spatially resolved mapping of functional checkpoint interactions in human melanoma tissues. Our findings demonstrate that receptor-ligand interactions diverge from checkpoint protein expression patterns and support further development of integrated approaches that contextualise functional checkpoint interactions within cellular features of the TiME. Such approaches may enable deeper investigation of checkpoint biology and inform the future development of functionally informed biomarkers for cancer immunotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s44276-026-00250-w","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:33:08Z","timestamp":1790749988000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Development of functional spatial mapping of the tumour immune microenvironment (FuncO:TiME) in advanced melanomas"],"prefix":"10.1038","volume":"4","author":[{"given":"Emma","family":"Wagner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Legg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Applebee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda R.","family":"Kirane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Padget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Banafsh\u00e9","family":"Larijani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"250_CR1","doi-asserted-by":"publisher","first-page":"e008646","DOI":"10.1136\/jitc-2023-008646","volume":"12","author":"DG Su","year":"2024","unstructured":"Su DG, Schoenfeld DA, Ibrahim W, Cabrejo R, Djureinovic D, Baumann R, et al. Digital spatial proteomic profiling reveals immune checkpoints as biomarkers in lymphoid aggregates and tumor microenvironment of desmoplastic melanoma. J Immunother Cancer. 2024;12:e008646. https:\/\/doi.org\/10.1136\/jitc-2023-008646.","journal-title":"J Immunother Cancer"},{"key":"250_CR2","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1158\/1078-0432.CCR-23-0215","volume":"29","author":"B Horowitch","year":"2023","unstructured":"Horowitch B, Lee DY, Ding M, Martinez-Morilla S, Aung TN, Ouerghi F, et al. Subsets of IFN signaling predict response to immune checkpoint blockade in patients with melanoma. Clin Cancer Res. 2023;29:2908\u201318. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-0215.","journal-title":"Clin Cancer Res"},{"key":"250_CR3","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.1158\/1078-0432.CCR-23-3932","volume":"30","author":"TN Aung","year":"2024","unstructured":"Aung TN, Warrell J, Martinez-Morilla S, Gavrielatou N, Vathiotis I, Yaghoobi V, et al. Spatially informed gene signatures for response to immunotherapy in melanoma. Clin Cancer Res. 2024;30:3520\u201332. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-3932.","journal-title":"Clin Cancer Res"},{"key":"250_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/2162402X.2023.2260618","volume":"12","author":"S Martinez-Morilla","year":"2024","unstructured":"Martinez-Morilla S, Moutafi M, Fernandez AI, Jessel S, Divakar P, Wong PF, et al. Digital spatial profiling of melanoma shows CD95 expression in immune cells is associated with resistance to immunotherapy. Oncoimmunology. 2024;12:1. https:\/\/doi.org\/10.1080\/2162402X.2023.2260618.","journal-title":"Oncoimmunology"},{"key":"250_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-025-00730-1","volume":"11","author":"I Zerdes","year":"2025","unstructured":"Zerdes I, Matikas A, Mezheyeuski A, Manikis G, Acs B, Johansson H, et al. Machine learning-based spatial characterization of tumor-immune microenvironment in the EORTC 10994\/BIG 1-00 early breast cancer trial. Npj Breast Cancer. 2025;11:23. https:\/\/doi.org\/10.1038\/s41523-025-00730-1.","journal-title":"Npj Breast Cancer"},{"key":"250_CR6","doi-asserted-by":"publisher","first-page":"4244","DOI":"10.1158\/0008-5472.CAN-20-1117","volume":"80","author":"L S\u00e1nchez-Magraner","year":"2020","unstructured":"S\u00e1nchez-Magraner L, Miles J, Baker CL, Applebee CJ, Lee DJ, Elsheikh S, et al. High PD-1\/PD-L1 checkpoint interaction infers tumor selection and therapeutic sensitivity to anti-PD-1\/PD-L1 treatment. Cancer Res. 2020;80:4244\u201357. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-1117.","journal-title":"Cancer Res"},{"key":"250_CR7","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1038\/s41416-021-01291-3","volume":"124","author":"B Larijani","year":"2021","unstructured":"Larijani B, Miles J, Ward SG, Parker PJ. Quantification of biomarker functionality predicts patient outcomes. Br J Cancer. 2021;124:1618\u201320. https:\/\/doi.org\/10.1038\/s41416-021-01291-3.","journal-title":"Br J Cancer"},{"key":"250_CR8","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.1002\/1873-3468.14480","volume":"596","author":"J Miles","year":"2022","unstructured":"Miles J, Ward SG, Larijani B. The fusion of quantitative molecular proteomics and immune-oncology: a step towards precision medicine in cancer therapeutics. FEBS Lett. 2022;596:2721\u201335. https:\/\/doi.org\/10.1002\/1873-3468.14480.","journal-title":"FEBS Lett"},{"key":"250_CR9","doi-asserted-by":"publisher","first-page":"5738","DOI":"10.3390\/cancers14235738","volume":"14","author":"J Miles","year":"2022","unstructured":"Miles J, Soubeyran I, Marliot F, Pangon N, Italiano A, Bellera C, et al. Determination of interactive states of immune checkpoint regulators in lung metastases after radiofrequency ablation. Cancers. 2022;14:5738. https:\/\/doi.org\/10.3390\/cancers14235738.","journal-title":"Cancers"},{"key":"250_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s44276-023-00033-7","volume":"2","author":"E Safrygina","year":"2024","unstructured":"Safrygina E, Applebee C, McIntyre A, Padget J, Larijani B. Spatial functional mapping of hypoxia inducible factor heterodimerisation and immune checkpoint regulators in clear cell renal cell carcinoma. BJC Rep. 2024;2:1. https:\/\/doi.org\/10.1038\/s44276-023-00033-7.","journal-title":"BJC Rep"},{"key":"250_CR11","doi-asserted-by":"publisher","unstructured":"Kirane AR, Lee D, Lowe M, Ahmad MU, Sharma S, Serasanambati M, et al. Toward functional biomarkers of response to neoadjuvant oncolytic virus in stage ii melanoma: immune-f\u00f6rster resonance energy transfer and the dynamic tumor immune microenvironment. JCO Oncol Adv. 2025. https:\/\/doi.org\/10.1200\/OA-24-00049.","DOI":"10.1200\/OA-24-00049"},{"key":"250_CR12","doi-asserted-by":"publisher","first-page":"2834","DOI":"10.1158\/0008-5472.CAN-05-2994","volume":"66","author":"A Kong","year":"2006","unstructured":"Kong A, Leboucher P, Leek R, Calleja V, Winter S, Harris A, et al. Prognostic value of an activation state marker for epidermal growth factor receptor in tissue microarrays of head and neck cancer. Cancer Res. 2006;66:2834\u201343. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-2994.","journal-title":"Cancer Res"},{"key":"250_CR13","doi-asserted-by":"publisher","first-page":"e2881","DOI":"10.1371\/journal.pone.0002881","volume":"3","author":"A Kong","year":"2008","unstructured":"Kong A, Calleja V, Leboucher P, Harris A, Parker PJ, Larijani B. HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells. PLoS ONE. 2008;3:e2881. https:\/\/doi.org\/10.1371\/journal.pone.0002881.","journal-title":"PLoS ONE"},{"key":"250_CR14","doi-asserted-by":"publisher","first-page":"4983","DOI":"10.1158\/0008-5472.CAN-13-3382","volume":"74","author":"S Veeriah","year":"2014","unstructured":"Veeriah S, Leboucher P, de Naurois J, Jethwa N, Nye E, Bunting T, et al. High-throughput time-resolved FRET reveals Akt\/PKB activation as a poor prognostic marker in breast cancer. Cancer Res. 2014;74:4983\u201395. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-3382.","journal-title":"Cancer Res"},{"key":"250_CR15","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.bbacli.2017.10.002","volume":"8","author":"J Miles","year":"2017","unstructured":"Miles J, Applebee CJ, Leboucher P, Lopez-Fernandez S, Lee DJ, Guarch R, et al. Time resolved amplified FRET identifies protein kinase B activation state as a marker for poor prognosis in clear cell renal cell carcinoma. BBA Clin. 2017;8:97\u2013102. https:\/\/doi.org\/10.1016\/j.bbacli.2017.10.002.","journal-title":"BBA Clin"},{"key":"250_CR16","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.soc.2025.01.006","volume":"34","author":"E Wagner","year":"2025","unstructured":"Wagner E, Larijani B, Kirane AR. Predictive biomarkers for immune checkpoint inhibitor therapy in advanced melanomas. Surg Oncol Clin N Am. 2025;34:437\u201351. https:\/\/doi.org\/10.1016\/j.soc.2025.01.006.","journal-title":"Surg Oncol Clin N Am"},{"key":"250_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-55387-w","volume":"14","author":"V Navikas","year":"2024","unstructured":"Navikas V, Kowal J, Rodriguez D, Rivest F, Brajkovic S, Cassano M, et al. Semi-automated approaches for interrogating spatial heterogeneity of tissue samples. Sci Rep. 2024;14:5025. https:\/\/doi.org\/10.1038\/s41598-024-55387-w.","journal-title":"Sci Rep"},{"key":"250_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21246-9","volume":"12","author":"S Jin","year":"2021","unstructured":"Jin S, Guerrero-Juarez CF, Zhang L, Chang I, Ramos R, Kuan CH, et al. Inference and analysis of cell-cell communication using CellChat. Nat Commun. 2021;12:1088. https:\/\/doi.org\/10.1038\/s41467-021-21246-9.","journal-title":"Nat Commun"},{"key":"250_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18873-z","volume":"11","author":"R Hou","year":"2020","unstructured":"Hou R, Denisenko E, Ong HT, Ramilowski JA, Forrest ARR. Predicting cell-to-cell communication networks using NATMI. Nat Commun. 2020;11:5011. https:\/\/doi.org\/10.1038\/s41467-020-18873-z.","journal-title":"Nat Commun"},{"key":"250_CR20","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1038\/nbt896","volume":"21","author":"EA Jares-Erijman","year":"2003","unstructured":"Jares-Erijman EA, Jovin TM. FRET imaging. Nat Biotechnol. 2003;21:1387\u201395. https:\/\/doi.org\/10.1038\/nbt896.","journal-title":"Nat Biotechnol"},{"key":"250_CR21","doi-asserted-by":"publisher","first-page":"7953","DOI":"10.3390\/curroncol29100629","volume":"29","author":"J Tong","year":"2022","unstructured":"Tong J, Kartolo A, Yeung C, Hopman W, Baetz T. Long-term toxicities of immune checkpoint inhibitor (ICI) in melanoma patients. Curr Oncol. 2022;29:7953\u201363. https:\/\/doi.org\/10.3390\/curroncol29100629.","journal-title":"Curr Oncol"},{"key":"250_CR22","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.pathol.2020.10.007","volume":"53","author":"EC Paver","year":"2021","unstructured":"Paver EC, Cooper WA, Colebatch AJ, Ferguson PM, Hill SK, Lum T, et al. Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation. Pathology. 2021;53:141\u201356. https:\/\/doi.org\/10.1016\/j.pathol.2020.10.007.","journal-title":"Pathology"},{"key":"250_CR23","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.3390\/jpm12071073","volume":"12","author":"S Marletta","year":"2022","unstructured":"Marletta S, Fusco N, Munari E, Luchini C, Cimadamore A, Brunelli M, et al. Atlas of PD-L1 for pathologists: indications, scores, diagnostic platforms and reporting systems. J Pers Med. 2022;12:1073. https:\/\/doi.org\/10.3390\/jpm12071073.","journal-title":"J Pers Med"},{"key":"250_CR24","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1002\/cyto.a.24789","volume":"103","author":"MC Marlin","year":"2023","unstructured":"Marlin MC, Stephens T, Wright C, Smith M, Wright K, Guthridge JM. A novel process for H&E, immunofluorescence, and imaging mass cytometry on a single slide with a concise analytics pipeline. Cytometry A. 2023;103:1010\u20138. https:\/\/doi.org\/10.1002\/cyto.a.24789.","journal-title":"Cytometry A"}],"container-title":["BJC Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44276-026-00250-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44276-026-00250-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44276-026-00250-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:03:02Z","timestamp":1790794982000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44276-026-00250-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["250"],"URL":"https:\/\/doi.org\/10.1038\/s44276-026-00250-w","relation":{},"ISSN":["2731-9377"],"issn-type":[{"value":"2731-9377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"assertion":[{"value":"2 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"BL is a Subject Editor for BJC Reports and recused herself from all decisions regarding this paper. The authors declare no other competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Stanford University CA USA - Institutional Review Board (IRB) and Certification of Human Subjects approval; March 19th, 2026; Awarded to Dr. Amanda Robinson Kirane, MD, Surgery - General Surgery at Stanford University; eProtocol #: 65607; IRB 5; Registration 4593; The IRB and Certification of Human subjects, consent was obtained from all participants. All methods in the manuscript were performed in accordance with the relevant guidelines and regulations of the IRB.","order":2,"name":"Ethics","label":"ETHICS APPROVAL AND CONSENT TO PARTICIPATE","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"48"}}